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Background. Palmitoylethanolamide (PEA) is emerging as a new therapeutic approach in pain and inflammatory conditions, and
it has been evaluated in studies on various painful diseases. +e aim of this open-label study was to evaluate the efficacy of
ultramicronized PEA (umPEA) in the prophylactic treatment of migraine.Methods. +e study included 70 patients with mean age
of 10.3± 2.7 (24.5%M and 75.5% F). All patients had a diagnosis of migraine without aura (ICHD 3 criteria) and received umPEA
(600mg/day orally) for three months. We compared the attack frequency (AF) and attack intensity at baseline and after three
months. Patients were asked to classify the intensity of the attack with a value ranging from 1 to 3, where 1 means mild attack, 2
moderate, and 3 severe attack. Results. Nine patients discontinued treatment before the target time of 12 weeks. After 3 months of
treatment with umPEA, the headache frequency was reduced by >50% per month in 63.9% patients. +e number of monthly
attacks at T1 decreased significantly compared with the baseline assessment (from 13.9± 7.5 SD of T0 to 6.5± 5.9 SD of T1;
p< 0.001). +e mean intensity of the attacks dropped from 1.67± 0.6 (T0) to 1.16± 0.5 (T1) (p< 0.001), and the percentage of
patients with severe attacks decreased after treatment (from 8.2% to 1.6%; p< 0.05). +e monthly assumptions of drugs for the
attack reduced from 9.5± 4.4 to 4.9± 2.5 (p< 0.001). Only one patient developed mild side effects (nausea and floating).
Conclusions. Our preliminary data show that umPEA administered for three month reduces pain intensity and the number of
attacks per month in pediatric patients with migraine. Although the small number of patients and the lack of control group do not
allow us to consider these initial results as definitely reliable, they encourage us to expand the sample.
1. Introduction
Migraine is a frequent disabling disorder in children and
adolescents, with recent meta-analytic data estimating its
prevalence at 7.7% in this age group [1, 2]. Episodic migraine
(EM), in which headache attacks involve less than 15 days
per month, affects approximately 5% of children up to the
age of 12 years and 11% of adolescents [3]. Chronic migraine
(CM) is very disabling and is characterized by 15 or more
days per month with headache for at least three months. CM
is not uncommon in the pediatric population affecting from
0.6% to 1.8% of children and adolescents [4–6]. Tradi-
tionally, pediatric migraine treatment includes both pro-
phylactic therapy, aiming at reducing the severity and
frequency of attacks and acute therapy to stop the attack
pain.
Although amitriptyline, topiramate, and flunarizine have
the most solid data supporting their use for migraine
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prophylaxis in children, a serious lack of controlled studies
on the pharmacological treatment still remains [7, 8].
In absence of consistent, high-quality efficacy data for
the use of pharmacologic preventive migraine interventions
targeted at children and adolescents, another modality worth
to be explored consists in the use of nonpharmacologic pill-
based interventions including nutraceuticals. Nutraceuticals
may be offered to parents who are reluctant to start their
child on a daily medication [8].
Despite nutraceuticals are largely used for prophylactic
treatment of children’s headache, there is a lack of official
guideline. Even the few available studies provide limited
evidence of nutraceutical efficacy [9]. +e most frequently
used nutraceuticals for headache’s prevention in children
and adolescents are magnesium, coenzyme Q10 (Cq10),
riboflavin, butterbur, melatonin, and preparations of fe-
verfew [9–11].
Palmitoylethanolamide (PEA) is an endogenous fatty
acid amide widely distributed in different tissues, including
nervous tissues. +is compound is naturally produced in
many plant and animal food sources as well as in cells and
tissues of mammals and endowed with important neuro-
protective, anti-inflammatory, and analgesic actions. Several
efforts have been made to identify the molecular mechanism
of action of PEA and explain its multiple effects both in the
central and the peripheral nervous system [12].
PEA has been reported to be effective in animal models
of chronic pain and inflammation as well as in several
clinical trials on various pain and inflammatory conditions.
[12–16].
However, to date, only one study has been conducted to
evaluate the role of PEA in migraine management in adults
with a statistically significant and time-dependent pain relief
[17].
+e aim of this open-label study was to evaluate the
safety and the efficacy of um-PEA in terms of reducing the
frequency and severity of migraine attacks in pediatric
patients.
2. Methods
We performed a prospective open-label study from January
2018 to January 2019 in patients admitted to the Headache
Center of Bambino Gesù Children Hospital in Rome. +e
Hospital Ethics Committee approved the study protocol,
and the parents of enrolled patients signed the written in-
formed consent.
2.1. Subject Recruitment. Inclusion criteria included diag-
nosis of episodic migraine without aura according to ICHD
3 criteria [18]: age between 5 and 17 years and high fre-
quency of the attacks (more than 4 attacks and less than 15
attacks for month). Exclusion criteria included the follow-
ing: chronic migraine according to ICHD 3; concomitant
history of medication overuse headache (MOH); treatment
with other prophylaxis drugs, including nutraceuticals, in
the three months prior to recruitment; progressive serious
clinical conditions (cancer, chronic hepatitis, and human
immunodeficiency virus); neuropsychiatric diseases (e.g.,
psychosis and depression, for the risk of low compliance),
renal diseases (serum creatinine concentration more than
1.2 times the upper limit of the normal range according to
the central laboratory reference values); and liver dysfunc-
tion (serum alanine or aspartate transaminase concentration
more than 1.5 times the upper limit of normal range
according to the central laboratory reference values).
In order to assess the efficacy of treatment, we compared
the monthly attack frequency (AF) and attack intensity (AI)
at baseline (T0) and after three months of therapy (T1).
Patients were asked to classify AI with a value ranging from 1
to 3 where 1 means mild attack, 2 moderate, and 3 severe
attack. +e primary endpoints were the reduction of the
frequency of the attacks more than 50% respect to the
baseline and the reduction of pain intensity of at least one
point.
2.2. Study Design. +e study was conducted in three phases.
A first (prescreening) visit was used to identify candidate
patients based on the inclusion criteria. +ese patients gave
written consent form to participate in the subsequent phases
of the study. In a second phase, the enrolled patients carried
out a one-month observation period where they reported on
a diary the frequency and intensity of attacks and the
number of intake of drugs for the attack. Baseline data were
then extrapolated from the patient diary. +ird, the patients
began the treatment phase during which they took umPEA
at doses of 600mg/day divided in two doses.
During the treatment phase, they continued to record
the data of frequency and intensity of the attacks and the
number of intake of drugs for the attack in a diary. Only data
from patients who completed a minimum 3-month therapy
period were considered for posttreatment data collection
(T1). Safety was assessed by monitoring the incidence of
adverse drug reactions (ADRs) which were classified
according to both severity and causality.
2.3. Statistical Analysis. Statistical analysis was conducted
with SPSS software version 22.0. +e differences between
multiple means before and after treatment were assessed
using T-student test and Wilcoxon signed-rank test. +e
linear mixed models (LMMs) were used to verify the effect of
different parameters (age, sex, and duration of treatment) on
the frequency and intensity of the attacks and assumption of
drugs before and after treatment with PEA (age, sex, and
duration of treatment). In particular, we adopted the gen-
eralized linear mixed model (GLMM) for evaluating the
effect on frequency and assumptions of drugs for the attack
(continuous variables) and cumulative linear mixed model
(CLMM) for the intensity of the attacks (categorial variable).
For both GLMM and CLMM, we assumed the Poisson
distribution and the models intercepted through link log an
individual female before the therapy as a reference subject.
Logistic regression was used to verify a correlation between
age and frequency of the attacks.
As for the dose of drug chosen, we referred to the
minimum effective dosage reported by other works on
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chronic pain, equal to 600mg/day. However, since the age
group of the subjects studied is very wide (from 6 to 17 years)
and this implies a variability of the wight of the subjects, we
tried to find per kilo dose considered effective. We then
calculated the average dosage per kilogram of body weight
for patients who achieved a reduction in the number of
attacks in T1 greater than 50%.
We therefore compared the results in three categories of
subjects: the patients who carried out the therapy for at least
12 weeks (group A), the dropout patients (group B: less than
12 week, side effects or incorrect reports), and the total
population (group A plus B).
+e significant level of statistical result was established
for p< 0.05.
3. Results
+e study included 69 patients with mean age of 10.43± 2.8
years (range between 5.4 and 17.6 years old). +e population
included 26.1% male and 73.9% female. All patients had a
diagnosis of episodic migraine without aura (ICHD 3 cri-
teria). In all enrolled patients, the laboratory parameters
were in the normal range, thus excluding systemic diseases.
No enrolled patients were receiving any prophylactic
treatment for migraine, but during the acute headache,
nonsteroidal anti-inflammatory drugs (NSAIDs) like ibu-
profen, paracetamol, diclofenac sodium, and ketorolac were
used.
Sixty-one children received umPEA (600mg/day orally)
for three months, while eight patients left the study earlier.
Main causes of dropout from the study included early
discontinuation of treatment (5/8 patients), incorrect
compilation of the diary (2/8) and reported side effects (1/8).
For patients with incorrect diary and side effects, we con-
sidered T1, the time when the correct report of the attacks
stopped or side effects were developed.+emean duration of
patients treated for less than 12 weeks was 4± 1 weeks.
3.1. Effects on Frequency of the Attacks. We found that, after
12 weeks of treatment with umPEA, the headache attack
frequency was reduced by >50% in 63.9% patients (vs 56.5%
of group B).
+e number of monthly attacks at T1 decreased signif-
icantly compared with the baseline assessment in the total
subject (from 14.06± 7.8 SD of T0 to 7.2± 6.4 SD of T1; mean
difference 6.85; p< 0.001) and in the group A (from
13.9± 7.5 SD of T0 to 6.5± 5.9 SD of T1; mean difference
7.30; p< 0.001) (Figure 1), while for group B, this difference
was not statistically significant (from 15.25± 10.1 SD of T0 to
12.5± 7.7 SD of T1; mean difference 2.75; p> 0.05).
+e GLMM showed that male subjects tend to have
fewer mean of attacks than females regardless of the time
considered (9.79± 0.7 SD for males vs 14.11± 0.5 SD of the
standard subject; linear coefficient: −0.37 vs 2.6 of the
standard subject; p � 0.01).
In addition, the GLMM shows us how the response to
therapy is strongly dependent on the duration of treatment;
in fact, patients who received the drug for at least 12 weeks
had a greater response than patients who took it for less time.
+e linear coefficient for patients receiving PEA in general is
−0.04 (vs 2.64 of the standard subject; p � 0.8), while for
patients treated at least 12 weeks, it is −0.6 (vs 2.65 of the
standard subject; p< 0.01).
We did not find any significant correlation between age
and the frequency of migraine attacks (p> 0.05) (Figure 2).
3.2. Effects on Intensity of the Attacks. We observed a re-
duction in intensity of the attacks from T0 to T1 in all the
three groups but with significant differences only for the
total population (from 1.71± 0.6 of T0 to 1.36± 0.5 of T1;
p< 0.001) and group A (from 1.67± 0.6 of T0 to 1.31± 0.5 of
T1; p< 0.001), while for group B, the difference was not
significant (from 2.0± 0.7 of T0 to 1.75± 0.7 of T1; p> 0.05).
For group A, the percentage of patients with severe attacks
decreased after treatment (from 8.2% to 1.6%; p< 0.05)
(Figure 3).
+e CLMM showed that male subjects tend to have less
intense attacks than females (linear coefficient: −2.21 vs the
standard subject; p< 0.01). Regarding the effect of duration
of treatment, we found that the linear coefficient for patients
receiving PEA in general is −1.3 (p � 0.2), while for patients
treated at least 12 weeks, it is −2.4 (p< 0.01).
3.3. Effects on theNumber ofMedicationsTaken for theAttack.
+e monthly assumption of drugs for the attack reduced
from 9.2± 4.3 to 5.68± 5.5 (p< 0.001) for general population
and from 9.5± 4.4 to 4.9± 2.5 (p< 0.001) (Figure 4), while
for group B, it decreased from 11.13± 7.5 to 10.5± 7.2
(p> 0.05).
+e GLMM showed no significant differences in male
and female for numbers of drug intake (8.28± 4.4 SD for
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Figure 1: Comparison of frequency of migraine attacks before and
after 12 weeks of treatment with umPEA.
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males vs 9.5± 4.4 SD of the standard subject; linear coeffi-
cient: −0.21 vs 2.3 of the standard subject; p � 0.1).
+e only parameter correlated with a reduction in the
intake of the drugs for the attacks that is identified by the
GLMM is the duration of treatment. +e linear coefficient
for patients receiving PEA regardless of the duration of
therapy is −0.17 (vs 2.34 of the standard subject; p> 0.05),
while for patients treated at least 12 weeks, it is −0.76 (vs 2.34
of the standard subject; p< 0.01).
3.4. Dosage and Tolerability. We found that patients who
had at least a 50% decrease in attack frequency after
treatment had received an average drug dose of 40mg/kd/
day of PEA.
Regarding safety, only one patient developed side effects
and consisted of nausea and floating.
4. Discussion
Our study showed that treatment of pediatric migrainous
patients with umPEA is well tolerated and improves the
frequency, intensity, and duration of the attacks. +ese ef-
fects are generally observed for a duration of treatment not
less than 12 weeks and at an average dosage of 40mg/kg/day
(maximum 600mg/day).
Migraine is a complex disease in which different bio-
chemical and neurophysiological abnormalities have been
described. Specific neuronal, glial, and vascular signaling
pathways involved in pathogenesis of migraine may rep-
resent distinct targets for acute and preventive migraine
therapies [19].
+e treatment of migraine in pediatric age encounters
numerous obstacles considering that traditional medicines
do not have the same evidence of efficacy as in adults, and
the new drugs against CGRP have not been systematically
tested in this age group. Furthermore, the high response to
placebo raises doubt about the actual need to treat migraine
children with drugs that may have adverse effects [20]. +is
is why the choice falls very often on nutraceuticals whose
efficacy data however remain conflicting [8].
4.1. PEA in Migraine Prophylactic Treatment. To date, only
one study has been conducted to evaluate the role of PEA in
migraine management in adults [17]. +e authors demon-
strated that umPEA administration to patients with MA
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Figure 3: Comparison of intensity of migraine attacks before and
after 12 weeks of treatment with umPEA.
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Figure 4: Comparison of monthly assumption of drugs for the
attack before and after 12 weeks of treatment with umPEA.
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Figure 2: Result of logistic regression for correlation between age
and response to treatment.
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(1,200mg/day for up 90 days) treated with commonNSAIDs
induced a significant pain relief irrespective to age or gender.
+ese effects were evident at 60 days after the beginning of
umPEA treatment and lasted throughout the study. +ese
results are in agreement with the previous reports showing
the antinociceptive action of umPEA in both preclinical
models of neuropathic pain and with clinical trials per-
formed in a variety of pain states [21].
In line with the study of Chirchiglia et al., our pilot study
showed that umPEA at low doses (600mg/kg/day) for short
period (three months) is effective in reducing migraine
attacks frequency and intensity in pediatric patients [17].
Our study also confirms the safety of treatment with
umPEA. Indeed, no severe adverse drug reactions or in-
teractions were recorded during the study highlighting an
optimal umPEA pharmacological profile, and the adherence
with the umPEA regimen was good.
Regarding the choice of the dose of umPEA to be ad-
ministered, we have referred to other studies in pediatric and
adult populations. In other pediatric diseases, such as acute
respiratory infections, the dosage of 50mg/kg (maximum
∼800mg /day), for the age groups between 1 and 6 years and
11 and 16 years, was found to be safe and effective [22, 23]. In
addition, the only study of umPEA in migraine used the
doses of 600mg/kg/day [17].
4.2. Possible Mechanisms of Action of PEA. PEA is an en-
dogenous fatty acid amide signaling molecule synthesized “on
demand” in response to tissue injury/stress, as part of a
mechanism to restore/maintain homeostasis with anti-in-
flammatory, pain-relieving, and neuroprotective actions
[24–27]. +is view is supported by studies showing that PEA
levels change in settings of tissue injury, especially in situations
associated with inflammatory and neurodegenerative processes
[27–30]. +e anti-inflammatory effects of PEA seem to be
mainly related to its ability to modulate mast cell (MC) acti-
vation and degranulation, and this action is also known as the
ALIA (autacoid local inflammation antagonism) mechanism
[31, 32]. In fact, MCs as well as glia possess endogenous ho-
meostatic mechanisms that can be upregulated because of tissue
damage or stimulation of inflammatory responses. Such mol-
ecules include the N-acylethanolamines, whose principal family
members are the endocannabinoid N-arachidonoylethanol-
amine (anandamide), and its congeners N-stearoylethanol-
amine, N-oleoylethanolamine, and PEA. In particular, PEA is
produced and hydrolyzed by microglia in response to stress
inflammatory events and it downmodulatesMC activation [25].
After the first description of the ALIA mechanism by Rita
Levi Montalcini [33], other direct and indirect mechanisms
explaining the PEA anti-inflammatory effects have been hy-
pothesized. +ough synergistic interactions involve several
mechanisms, PEA can produce its important therapeutic effects,
in both the central and peripheral nervous systems [12]. +e
direct targets of the PEA are two receptors: the PPAR-α [34] and
the orphanGPR55 (GPR55) [35]. PEA has an agonist activity on
the PPAR-α receptor that is a gene expression factor that
promotes the expression of genes with anti-inflammatory ac-
tivity [36]. GPR55 shows a low homology with cannabinoid
receptors CB1 and CB2. It has been reported that GPR55 uses a
variety of downstream signing events with regulatory effects of
neuroinflammation [31]. +e indirect effects of PEA are on the
CB1 and CB2 receptors, the fatty acid amide hydrolase (FAAH)
factor, and the transient receptor potential vanilloid 1 (TRPV1)
receptor channel. +rough the inhibition of the FAAH ex-
pression, PEA may increase the endogenous levels of ananda-
mide (AEA) which directly activate CB2 or CB1 receptors and
TRPV1 channels (entourage effect) [12, 37].+e final effect is an
activation of CB1 and CB receptor and desensitization TRPV1
channel [38]. CB1 is expressed in brain tissue and regulates
neuronal transmission [27]. CB2 is expressed on mast cells,
activated microglia, controls inflammation, and nociceptive
signals [26]. TRPV1 channel receptors are widely expressed in
small sensory C and A delta fiber.+ey have also been observed
in the central nervous system and in physiologicalmembranes of
several tissues. TRPV1 have also been observed in many organs,
and their increased expression contributes to development and
perception of the somatic and visceral pain. +e process of
TRPV1 inactivation, also known as “desensitization,” contrib-
utes to the analgesic and anti-inflammatory actions of TRPV1
agonists [39].
PEA is produced and hydrolyzed by microglia [40], and
through several abovementioned mechanisms, it inhibits mast
cell activation [31, 41]. Although PEA has been studied in
several inflammatory diseases, there are very few data on its
efficacy in migraine. +e recent observation of mast cell in-
volvement in some mechanism of migraine could explain the
efficacy of this molecule for the treatment of this condition [42].
+e effect of MCs resident in the meninges can play a
critical role in the development of inflammation in many
diseases, including migraine [43]. Since several original
studies by+eoharides et al. [44], the role of meningeal mast
cells as triggers of migraine attacks was further explored by
others, showing the pronociceptive role of mast cell derived
from proinflammatory cytokines and chemokines
[42, 43, 45, 46]. MCs are densely present in meningeal
tissues, located adjacent to both nerves and vessels [43, 44].
+e contact between MCs and nerve endings forms a
neuroimmune synapse where active substances released by
MCs can activate neighboring nociceptive fibers, and
compounds released from active fibers, in turn, can
degranulate MCs [47]. Degranulation of dural MCs can
strongly activate meningeal nerve fibers [48]. In fact, acti-
vated MCs release preformed mediators including hista-
mine, heparin, proteases (tryptase and chimase), hydrolases,
cathepsin, carboxypeptidases, and peroxidase, and they also
generate proinflammatory cytokines and chemokines. In
addition, activated macrophages, microglia, and MCs in the
CNS release proinflammatory cytokines which provoke an
increase of arachidonic acid product levels and lead to
migraine and other neurological manifestations including
fatigue, nausea, headaches, and brain fog [46].
4.3. Limitations of the Study. We must underline that this
study has some limitations represented. First, we did not use a
placebo-controlled design. Given the huge effect of placebo
demonstrated in the prophylaxis of pediatric migraine [49], the
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lack of a control group treated with placebo prevents us to reach
a definitive conclusion about umPEA efficacy. Second, although
the umPEA was effective in most our patients, the studied
sample was relatively small.+ird, our follow-up was brief, thus
preventing us to have data about the duration of the umPEA
effect. In spite of all these limitations, our pilot study represents
the first investigation about the possible efficacy of the umPEA
in pediatric migraine. Of course, the present promising results
need to be confirmed in a larger population and after com-
parison with placebo.
5. Conclusion
Although PEA is not reported in guidelines of migraine
treatment in pediatric age, in our study, the administration
of umPEA to pediatric patients with migraine induced a
significant pain relief and reduction of the number of mi-
graine attacks. No major adverse drug reactions or inter-
actions were recorded during the study. +ese data,
suggesting an optimal pharmacological profile, lead us to
conclude that PEA should be considered for prophylactic
treatment of migraine in children.
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